Back to Search
Start Over
Surprise FDA rejection halts Sesen Bio's launch in its tracks, putting newly hired sales team in limbo
- Source :
- Fiercepharma.com. August 17, 2021
- Publication Year :
- 2021
-
Abstract
- Byline: Beth Snyder Bulik Last week, Sesen Bio was finalizing label wording with the FDA on its bladder cancer hopeful Vicineum. This week, the CEO is explaining to investors how [...]
- Subjects :
- Pharmaceuticals and cosmetics industries
Subjects
Details
- Language :
- English
- Database :
- Gale General OneFile
- Journal :
- Fiercepharma.com
- Publication Type :
- News
- Accession number :
- edsgcl.672317661